

Penumbra System<sup>™</sup> · RED 72 Reperfusion Catheter

## Penumbra System™ · RED™72

Catalog Number	Description	Proximal OD (F) (in.) (mm)	Distal OD (mm)	Proximal ID (in.) (mm)	Distal ID (in.) (mm)	Working Length (cm)
Penumbra System	1					
ASPIRATION KITS	3					
RED72KIT	RED 72 Reperfusion Catheter + Penumbra Aspiration Tubing	6 (.085) (2.16)	2.16	.072 (1.83)	.072 (1.83)	132
RED68KIT	RED 68 Reperfusion Catheter + Penumbra Aspiration Tubing	6 (.084) (2.13)	2.13	.068 (1.73)	.068 (1.73)	132
RED62SKIT	RED 62 Reperfusion Catheter + Penumbra Aspiration Tubing	6 (.076) (1.93)	1.93	.062 (1.57)	.062 (1.57)	138
REPERFUSION CA	THETERS					
RED72	RED 72 Reperfusion Catheter	6 (.085) (2.16)	2.16	.072 (1.83)	.072 (1.83)	132
RED68	RED 68 Reperfusion Catheter	6 (.084) (2.13)	2.13	.068 (1.73)	.068 (1.73)	132
RED62S	RED 62 Reperfusion Catheter	6 (.076) (1.93)	1.93	.062 (1.57)	.062 (1.57)	138
3MAXC	3MAX™ Reperfusion Catheter	4.7 (.062) (1.57)	1.27	.043 (1.09)	.035 (.89)	160
REVASCULARISAT	TION DEVICE	Diameter	Device Length	Working Length		
PSR3D	3D Revascularization Device™	4.5 mm	26 mm	20 mm		
DELIVERY MICRO	CATHETER					
VEL160STR	Velocity™ Microcatheter	2.95 (.0387) (.983)	.867	.025 (.635)	.025 (.635)	160
ASPIRATION ACC	ESSORIES					
PMXENGN	Penumbra ENGINE™					
PAPS3	Penumbra ENGINE Canister					

Prior to use, please refer to the Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse

### PENUMBRA SYSTEM - Intended Use

The PENUMBRA SYSTEM is intended to remove thrombus and restore blood flow in the neurovasculature using aspiration.

Potential Adverse Events

Possible complications include, but are not limited to, the following: allergic reaction and anaphylaxis from contrast media or device material; acute vessel occlusion; air embolism; arteriovenous fistula; death; foreign body embolization; emboli; pseudoaneurysm; hematoma or hemorrhage at access site; residual thrombus due to inability to completely remove thrombus; infection; inflammation; intracranial hemorrhage; ischemia; renal impairment or acute renal failure from contrast media; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; radiation exposure that may lead to cataracts, skin reddening, burns, alopecia, or neoplasia from x-ray exposure.

PENUMBRA SYSTEM - Intended Use
The PENUMBRA SYSTEM is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease using continuous aspiration.

## Potential Adverse Events

Possible complications include, but are not limited to, the following: allergic reaction and anaphylaxis from contrast media; acute occlusion; air embolism; arteriovenous fistula; death; device malfunction; distal embolization; emboli; false aneurysm formation; hematoma or hemorrhage at access site; inability to completely remove thrombus; infection; intracranial hemorrhage; ischemia; kidney damage from contrast media; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; radiation exposure that may lead to cataracts, skin reddening or burns from x-ray exposure.

Prior to use, please refer to the Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use.

PENUMBRA SYSTEM – Intended Use
The PENUMBRA SYSTEM is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease using continuous aspiration.

Potential Adverse Events
Possible complications include, but are not limited to, the following: allergic reaction and anaphylaxis from contrast media; acute occlusion; air embolism; arteriovenous fistula; death; device malfunction; distal embolization; emboli; false aneurysm formation; hematoma or hemorrhage at access site; inability to completely remove thrombus; infection; intracranial hemorrhage; ischemia; kidney damage from contrast media; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; radiation exposure that may lead to cataracts, skin reddening, burns, alopecia, or neoplasia from x-ray exposure.

PENUMBRA ENGINE – Intended Use
The PENUMBRA ENGINE is intended as a vacuum source for Penumbra Aspiration Systems.

Penumbra Delivery Microcatheters – Intended Use
The Penumbra Delivery Microcatheters are intended to assist in the delivery of diagnostic agents, such as contrast media, and therapeutic agents, such as occlusion coils to the peripheral and neuro vasculature.

## Potential Adverse Events

Possible complications include, but are not limited to, the following: acute occlusion; hematoma or hemorrhage at access site; death; intracranial hemorrhage; infection (at access site); distal embolization; ischemia (cardiac and/or cerebral); embolus (air, foreign body, thrombus, plaque); aneurysm perforation; false aneurysm formation; neurological deficits including stroke; vessel spasm, thrombosis, dissection, perforation or rupture; air embolism; emboli.

Penumbra Europe GmbH Penumbra, Inc. USA Am Borsigturm 44 One Penumbra Place 13507 Berlin Alameda, CA 94502 Germany USA


T +49 30 2005 676-0 1.888.272.4606 F +49 30 2005 676-10 T 1.510.748.3200 de-order@penumbrainc.com F 1.510.748.3232 de-info@penumbrainc.com order@penumbrainc.com info@penumbrainc.com

Photograph taken by and on file at Penumbra, Inc.


Product availability varies by country. Please contact your local Penumbra representative for more information.




## Penumbra System Setup



## **Reperfusion Catheter Dimensions**





Product availability varies by country. Prior to use, please refer to the Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. A summary of this information is included on the back of this poster. Procedural and operative techniques and considerations are illustrative examples from physicians ir treatment and technique decisions will vary based on their medical judgment. Photographs taken by and on file at Penumbra, Inc. Renderings for illustrative purposes only. Individual results may vary depending on a variety of patient-specific attributes and other factors. Please contact your local Penumbra representative for more information.

Am Borsigturm 44 13507 Berlin Germany T +49 30 2005 676-0 F +49 30 2005 676-10

de-info@penumbrainc.com

Penumbra Europe GmbH

Penumbra, Inc. USA
One Penumbra Place
Alameda, CA 94502
USA
1.888.272.4606
T 1.510.748.3200
F 1.510.748.3232
order@penumbrainc.com
info@penumbrainc.com



Prior to use, please refer to the Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use.

PENUMBRA SYSTEM – Intended Use
The PENUMBRA SYSTEM is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease using

## Potential Adverse Events

Possible complications include, but are not limited to, the following: allergic reaction and anaphylaxis from contrast media; acute occlusion; air embolism; arteriovenous fistula; death; device malfunction; distal embolization; emboli; false aneurysm formation; hematoma or hemorrhage at access site; inability to completely removze thrombus; infection; intracranial hemorrhage; ischemia; kidney damage from contrast media; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; radiation exposure that may lead to cataracts, skin reddening or burns from x-ray exposure.

### PENUMBRA SYSTEM – Intended Use The PENUMBRA SYSTEM is intended to remove thrombus and restore blood flow in the

Potential Adverse Events

Possible complications include, but are not limited to, the following: allergic reaction and anaphylaxis from contrast media or device material; acute vessel occlusion; air embolism; arrhythmia; arteriovenous fistula; death; foreign body embolization; emboli; pseudoan-

eurysm; hematoma or hemorrhage at access site; residual thrombus due to inability to completely remove thrombus; infection; inflammation; intracranial hemorrhage; ischemia; renal impairment or acute renal failure from contrast media; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; radiation exposure that may lead to cataracts, skin reddening, burns, alopecia, or neoplasia from x-ray exposure

## PENUMBRA SYSTEM - Intended Use

The PENUMBRA SYSTEM is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease using

Possible complications include, but are not limited to, the following: allergic reaction and anaphylaxis from contrast media; acute occlusion; air embolism; arteriovenous fistula; death; device malfunction; distal embolization; emboli; false aneurysm formation; hema-toma or hemorrhage at access site; inability to completely remove thrombus; infection; intracranial hemorrhage; ischemia; kidney damage from contrast media; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; radiation exposure that may lead to cataracts, skin reddening, burns, alopecia, or neoplasia from

## PENUMBRA ENGINE – Intended Use

The PENUMBRA ENGINE is intended as a vacuum source for Penumbra Aspiration

NEURON MAX System – Intended Use
The NEURON MAX System is intended for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature Potential Adverse Events
Possible complications include, but are not limited to, the following: acute occlusion; air


embolism; death; distal embolization; emboli; false aneurysm formation; hematoma or hemorrhage at puncture site; infection; intracranial hemorrhage; ischemia; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation.


## Penumbra Delivery Microcatheters - Intended Use

The Penumbra Delivery Microcatheters are intended to assist in the delivery of diagnostic agents, such as contrast media, and therapeutic agents, such as occlusion coils to the peripheral and neuro vasculature.

Potential Adverse Events
Possible complications include, but are not limited to, the following: acute occlusion; hematoma or hemorrhage at access site; death; intracranial hemorrhage; hemorrhage; infection (at access site); distal embolization; ischemia (cardiac and/or cerebral); embolus (air, foreign body, thrombus, plaque); aneurysm perforation; false aneurysm formation; neurological deficits including stroke; vessel spasm, thrombosis, dissection,

## Penumbra System™ Stroke Procedure Devices





## **Ordering Information**

## Penumbra System™

Catalog Number	Description	Proximal OD (F) (in.) (mm)	Distal OD (F) (in.) (mm)	Proximal ID (in.) (mm)	<b>Distal ID</b> (in.) (mm)	Working Length (cm)
Reperfusion Catheters						
5MAXJET7	Penumbra JET™ 7 Reperfusion Catheter with Standard Tip	6 (.085) (2.16)	6 (.085) (2.16)	.072 (1.83)	.072 (1.83)	132
5MAXJETD	Penumbra JET D Reperfusion Catheter	6 (.080) (2.03)	5 (.065) (1.65)	.064 (1.63)	.054 (1.37)	138
5MAXACE068	ACE™68 Reperfusion Catheter	6 (.080) (2.03)	6 (.080) (2.03)	.068 (1.73)	.068 (1.73)	132
5MAXACE132	ACE60 Reperfusion Catheter	6 (.080) (2.03)	5.4 (.071) (1.80)	.068 (1.73)	.060 (1.52)	132
PSC054	5MAX™ Reperfusion Catheter	6 (.080) (2.03)	5 (.065) (1.65)	.064 (1.63)	.054 (1.37)	132
4MAXC	4MAX Reperfusion Catheter	6 (.080) (2.03)	4.3 (.056) (1.42)	.064 (1.63)	.041 (1.04)	139
3MAXC	3MAX Reperfusion Catheter	4.7 (.062) (1.57)	3.8 (.050) (1.27)	.043 (1.09)	.035 (.89)	160
Revascularisation Device			Diameter (mm)	Device Length (mm)		(mm)
PSR3D	3D Revascularization Device™	n/a	4.5	26	n/a	20
Delivery Microcatheter						
VEL160STR	Velocity™ Microcatheter	2.95 (.0387) (.983)	2.6 (.034) (.867)	.025 (.635)	.025 (.635)	160

### **Aspiration Accessories**

PMXENGN Penumbra ENGINE™ PAPS3 Penumbra ENGINE Canister PST2 MAX Aspiration Tubing

## Neuron MAX™ 088 6 F Long Sheath

Catalog Number	Description	Tip Shape	Working Length (cm)	<b>Distal Flexible Zone</b> (cm)	Inner Diameter (in.) (mm)		
(Crosscut Valve, RHV, and Dilator Included)							
PNML6F088804	Neuron MAX 088 6 F Long Sheath, 80/4 Straight	Ī	80	4	.088 (2.24)		
PNML6F088804M	Neuron MAX 088 6 F Long Sheath, 80/4 MP	₫	80	4	.088 (2.24)		
PNML6F088904	Neuron MAX 088 6 F Long Sheath, 90/4 Straight	Ī	90	4	.088 (2.24)		
PNML6F088904M	Neuron MAX 088 6 F Long Sheath, 90/4 MP	1	90	4	.088 (2.24)		
PNML6F0881004	Neuron MAX 088 6 F Long Sheath, 100/4 Straight	Ī	100	4	.088 (2.24)		
PNML6F0881004M	Neuron MAX 088 6 F Long Sheath, 100/4 MP	Ñ	100	4	.088 (2.24)		

### 6 F Select™ Catheters

Catalog Number	Description	Tip Shape	<b>Working Length</b> (cm)	Distal Flexible Zone (cm)	Inner Diameter (in.) (mm)
PNS6F105H1	6 F Select Catheter, 105 H1	5	105	9	.040 (1.02)
PNS6F105BER	6 F Select Catheter, 105 BER	<b>1</b>	105	9	.040 (1.02)
PNS6F125H1	6 F Select Catheter, 125 H1	5	125	9	.040 (1.02)
PNS6F125SIM	6 F Select Catheter, 125 SIM	4	125	9	.040 (1.02)
PNS6F125SIMV	6 F Select Catheter, 125 SIM-V	Š	125	9	.040 (1.02)
PNS6F125BER	6 F Select Catheter, 125 BER	1	125	9	.040 (1.02)

Prior to use, please refer to the instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use.

## PENUMBRA SYSTEM - Intended Use

The PENUMBRA SYSTEM is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease using continuous aspiration.

Potential Adverse Events
Possible complications include, but are not limited to, the following:
allergic reaction and anaphylaxis from contrast media; acute occlusion;
air embolism; arteriovenous fistula; death; device malfunction; distal air empoilsm; arteriovenous fistula; death; device malfunction; distal embolization; emboli; false aneurysm formation; hematoma or hemorrhage at access site; inability to completely remove thrombus; infection; intracranial hemorrhage; ischemia; kidney damage from contrast media; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; radiation exposure that may lead to cataracts, skin reddening or burns from x-ray exposure.

PENUMBRA SYSTEM – Intended Use
The PENUMBRA SYSTEM is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease using continuous aspiration.

Potential Adverse Events
Possible complications include, but are not limited to, the following:
allergic reaction and anaphylaxis from contrast media; acute occlusion;
air embolism; arteriovenous fistula; death; device malfunction; distal embolization, emboli; false aneurysm formation; hematoma or hemorrhage at access site; inability to completely remove thrombus; infection; intracranial hemorrhage; ischemia; kidney damage from contrast media; neurological deficits including stroke; vessel spasm, thrombosis, dissection, or perforation; radiation exposure that may lead to cataracts, skin reddening, burns, alopecia, or neoplasia from x-ray exposure.

## PENUMBRA ENGINE – Intended Use

The PENUMBRA ENGINE is intended as a vacuum source for Penumbra Aspiration Systems.

NEURON MAX System – Intended Use
The NEURON MAX System is intended for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.

## Potential Adverse Events

Possible complications include, but are not limited to, the following acute occlusion; alrembolism; death; distal embolization; emboli; false aneurysm formation; hematoma or hemorrhage at puncture site; infection; intracarnial hemorrhage; ischemia; neurological deficts including stroke; vessel spasm, thrombosis, dissection, or perforation.

## Penumbra Delivery Microcatheters – Intended Use

The Penumbra Delivery Microcatheters are intended to assist in the delivery of diagnostic agents, such as contrast media, and therapeutic agents, such as occlusion coils to the peripheral and neuro vasculature.

## Potential Adverse Events

Potential Adverse Events
Possible complications include, but are not limited to, the following:
acute occlusion; hematoma or hemorrhage at access site; death; intracranial
hemorrhage; hemorrhage; infection (at access site); distal embolization;
ischemia (cardiac and/or cerebral); embolus (air, foreign body, thrombus,
plaque); aneurysm perforation; false aneurysm formation; neurological
deficits including stroke; vessel spasm, thrombosis, dissection, perforation
or rupture; air embolism; emboli.

Penumbra Europe GmbH


Am Borsigturm 44 13507 Berlin T +49 30 2005 676-0 F +49 30 2005 676-10 de-order@penumbrainc.com de-info@penumbrainc.com

Penumbra, Inc. USA One Penumbra Place Alameda, CA 94502

USA 1.888.272.4606 T 1.510.748.3200 F 1.510.748.3232 order@penumbrainc.com info@penumbrainc.com



## Penumbra System






## **Hollow Tube Design Lacks Intraluminal Clot Capture**

## Hollow tube design

pushes clot to edge of device, increasing potential to shear clot



## Next Generation Technology Engineered to Retrieve Clot

## Intraluminal chambers


lock clot centrally within device for withdrawal into ACE Reperfusion Catheter



# First Generation Hollow Tube Design

## Hollow tube design


expands and pushes clot against vessel wall, increasing potential for downstream emboli




## ACE68 + 3D System Optimised to Reduce Clot Shearing

## Intraluminal chambers

designed to lock clot within center of device, potentially reducing risk of clot shearing



ACE68 Reperfusion Catheter optimally sized to provide 2.8× more clot capture in the M1 than 8 F BGC' in the ICA'



nderings are for illustrative purposes only. Individual results may vary depending on a variety of patient-specific attributes.

- 1. 8 F Balloon Guide Catheter (BGC) measurement based on 8 F Stryker® FlowGate<sup>2®</sup>
- Vessel diameters used are common clinical measurements.
   Tests performed and data on file at Penumbra, Inc. Bench test results may not be indicative of clinical performance

## 3D Revascularization Device Case Examples







Images courtesy of Dr. Zeguang Ren Tampa General Hospital, FL, USA







Images courtesy of Dr. Raj Agrawal Desert Radiology, Las Vegas, NV, USA

## Penumbra System

Catalog Number	Description	Proximal OD	Distal OD	Proximal ID	Distal ID	Working Length
Aspiration Kits						4900, 1900
5MAXACE068KIT	ACE68 Reperfusion Catheter+Penumbra Hi-Flow Tubing	6.0 F (.080")	6.0 F	.068"	.068"	132 cm
5MAXACE064KIT	ACE64 Reperfusion Catheter+Penumbra Hi-Flow Tubing	6.0 F (.080")	5.75 F	.068"	.064"	132 cm
5MAXACE132KIT	ACE60 Reperfusion Catheter+Penumbra Hi-Flow Tubing	6.0 F (.080")	5.4 F	.068"	.060"	132 cm
PSC054KIT	5MAX Reperfusion Catheter+Penumbra Hi-Flow Tubing	6.0 F (.080")	5.0 F	.064"	.054"	132 cm
4MAXCKIT	4MAX Reperfusion Catheter+Penumbra Hi-Flow Tubing	6.0 F (.080")	4.3 F	.064"	.041"	139 cm
3MAXCKIT	3MAX Reperfusion Catheter+Penumbra Hi-Flow Tubing	4.7 F (.062")	3.8 F	.043"	.035"	153 cm
Revascularisation Device		Diameter	Device Length	Working Length		***************************************
PSR3D	3D Revascularization Device	4.5 mm	26 mm	20 mm		
Delivery Microcatheter						

### Penumbra System with 3D Revascularization Device - Indication For Use

Penumbra System with 3D Revascularization Device – Indication For Use Penumbra System Reperfusion Catheters and Separators
As part of the Penumbra System, the Reperfusion Catheters and Separators are indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral — M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom set. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

Penumbra 3D Revascularization Device
As part of the Penumbra System, the Penumbra 3D Revascularization Device is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral — M1 and M2 segments) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

Penumbra Aspiration Tubing
As part of the Penumbra System, the Penumbra Sterile Aspiration Tubing is indicated to connect the Penumbra Reperfusion Catheters to the Penumbra Aspiration Pump.

Velocity Microcatheter

Penumbra Aspiration Pump
The Penumbra Aspiration Pump is indicated as a vacuum source for Penumbra Aspiration Systems.

Contraindications
There are no known contraindication

VEL160STR

- There are no known contraindications.

  Warnings

  The Penumbra System should only be used by physicians who have received appropriate training in interventional neuroendovascular techniques and treatment of acute ischemic stroke.

  Do not advance, retract or use any component of the Penumbra System against resistance without careful assessment of the cause using fluoroscopy. If the cause cannot be determined, withdraw the device or system as a unit, Unrestrained torquing or forced insertion of the catheter, revascularization device, or Separator against resistance may result in damage to the device or vessel.

  Do not use the Penumbra System with a pump other than the Penumbra Aspiration Pump.

  The Penumbra 3D Revascularization Device has not been evaluated in patients with angiographic evidence of pre-existing arterial injury.

Precautions

- The device is intended for single use only. Do not resterilize or reuse. Resterilization and/or Reuse may result in ineffective catheter coating lubrication, which may result in high friction and the inability to access the target neuro vasculature
- Carriette Column Colors (Colors) (Color
- and packaging to the manufacturer/distributor.

- to the manufacturer/distributor.

   Use prior to the "Use By" date.
   Use the Penumbra System in conjunction with fluoroscopic visualization.

   Maintain a constant infusion of appropriate flush solution.

   Maintain a constant infusion of appropriate flush solution.

   When performing aspiration, ensure that the Penumbra Aspiration Tubing valve is open for only the minimum time needed to remove thrombus. Excessive aspiration or failure to close the Penumbra Aspiration Tubing valve when aspiration is complete is not recommended.

   The Penumbra Separator is not intended for use as a neurovascular guidewire. If repositioning of the Penumbra Repertusion Catheter is necessary during the revascularization procedure, such repositioning should be performed over an appropriate neurovascular guidewire using standard microcatheter and guidewire techniques.

   Do not use automated high-pressure contrast injection equipment with the Penumbra Repertusion Catheter because it may damage the device.

   Administration of anticoagulants and antiplatelets should be suspended until 24 hours post-treatment. Medical management and acute post stroke care should follow the ASA guidelines. Any neurological deterioration should be evaluated by urgent CT scan and other evaluations as indicated according to investigator/hospital best practice.

urgent CT scan and other evaluations as indicated according to investigator/hospital best practice.

- As in all surgical interventions, monitoring of intra-procedural blood loss is recommended so that appropriate management may be instituted.

- Limit the usage of Repertusion Catheters to arteries larger than the catheter's outer diameter. Potential Adverse Events

Possible complications include, but are not limited to, the following: allergic reaction and anaphylaxis from contrast media, acute occlusion, air embolism, arteriovenous fistula, death, device malfunction, distal embolization, emboli, false aneurysm formation, hematoma or hemorrhage at access site, inability to completely remove thrombus, infection, intracranial hemorrhage, ischemia, kidney damage from contrast media, neurological deficits including stroke, vessel spasm, thrombosis, dissection, or perforation.

Penumbra System – Indication For Use
Penumbra System Reperfusion Catheters and Separators – Indication For Use
As part of the Penumbra System, the Reperfusion Catheters and Separators are indicated for use in the revascularization of
patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle
cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset.
Penumbra Aspiration Tubing – Indication For Use
As part of the Penumbra System, the Penumbra Sterile Aspiration Tubing is indicated to connect the Penumbra Reperfusion
Catheters to the Penumbra Pump MAX.
Contraintications

Contraindications There are no known contraindications.

- Warnings

  The Penumbra System should only be used by physicians who have received appropriate training in interventional neuro-endovascular techniques and treatment of acute ischemic stroke.

  Do not advance, retract or use any component of the Penumbra System against resistance without careful assessment of the cause using fluoroscopy. If the cause cannot be determined, withdraw the device or system as a unit. Unrestrained torquing or forced insertion of the catheter or separator against resistance may result in damage to the device or vessel.

  Do not use the Penumbra System with a pump other than the Penumbra Aspiration Pump.

  Procentings

- The device is intended for single use only. Do not resterilize or reuse. Resterilization and/or Reuse may result in ineffective catheter coating lubrication, which may result in high friction and the inability to access the target neuro vasculature location.

  Do not use kinked or damaged devices. Do not use open or damaged packages. Return all damaged devices and packaging to the manufacturer/distributor.

  Use prior to the "Use By" date.

  Use the Penumbra System in conjunction with fluoroscopic visualization.

  Maintain a constant infusion of appropriate flush solution.

  Maintain a constant infusion of appropriate flush solution.

  When performing aspiration, ensure the Penumbra Aspiration Tubing valve is open for only the minimum time needed to remove thrombus. Excessive aspiration or failure to close the Penumbra Aspiration Tubing valve when aspiration is complete is not recommended.

  The Penumbra Separator is not intended for use as a neurovascular guidevire. If repositioning of the Penumbra Reperfusion Catheter is necessary during the revascularization procedure, such reposition should be performed over an appropriate neurovascular guidevire using standard microcatheter and guidevire techniques.

  Do not use automated high-pressure contrast injection equipment with the Penumbra Reperfusion Catheter because it may damage the device.
- Do not use automated high-pressure contrast injection equipment with the Penumbra Repertusion Catheter because it may damage the device.
   Administration of anticoagulants and antiplatelets should be suspended until 24 hours post-treatment. Medical management and acute post storike care should follow the ASA guidelines. Any neurological deterioration should be evaluated by urgent CT scan and other evaluations as indicated according to investigator/forspiral best practice.
   The total time allowed to achieve patient revascularization is 120 minutes of using the Penumbra System.

- As in all surgical interventions, monitoring of intra-procedural blood loss is recommended so that appropriate management

- may be instituted.

  Limit the usage of Reperfusion Catheters in arteries larger than the catheter's outer diameter.

  Potential Adverse Events

  Possible complications include, but are not limited to, the following:

  allergic reaction and anaphylaxis from contrast media, acute occlusion, air embolism, arteriovenous fistula, death, device malfunction, distal embolization, emboli, false aneurysm formation, hematoma or hemorrhage at access site, inability to completely remove thrombus, infection, intracranial hemorrhage, ischemia, kidney damage from contrast media, neurological deficits including stroke, vessel spasm, thrombosis, dissection, or perforation
- 1. Adams et al., Guidelines for the Early Management of Adults with Ischemic Stroke: A Guideline from the AHA/ASA Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vas-cular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists, Stroke May 2007; 38: 1655-1711.

### Penumbra Pump MAX - Indication For Use

- Penumbra Pump MAX Indication For Use
  The Penumbra Pump MAX is indicated as a vacuum source for the Penumbra Aspiration Systems.
  Contraindications
  There are no contraindications,
  Warnings/Precautions

  The canister/tubing is intended for single use only. Do not reuse. Reuse may result in canister cracking or tubing blockages, which may result in the inability to aspirate.

  Do not block bottom or back air vents. Unit may overheat and shut off or fail to restart if run for extended periods of time
- without arrive.

  To avoid risk of electric shock, this equipment must only be connected to a supply mains with protective earth. Do not position the pump so that it is difficult to operate the power cord disconnection device. Remove and service the pump if liquids or solids have been drawn into the vacuum pump. Do not use in the presence of flammable anaesthetic mixture with air or nitrous oxide.

- Do not use in the presence of nammable anaesthetic mixture with air or nitrous oxide.
   Do not use in oxygen rich environment.
   To prevent fire or shock hazard, use replacement fuses of equal size and rating.
   To prevent fire or shock hazard, use a replacement power cord of equal rating.
   Do not re-infuse blood or fluid from the canister back into patient.
   Do not use petroleum base compounds, acids, caustics, or chlorinated solvents to clean or lubricate any parts. It will reduce service life of the pump. Use only water-base solvents for cleaning.
   Federal (USA) law restricts this device to sale by or on the order of a physician.
- · No modification of this equipment is allowed.

Neuron MAX System – Indication For Use
The Neuron MAX System is indicated for the introduction of interventional devices into the peripheral, coronary,
and neuro vasculature.

Contraindications

There are no known contraindications.

- Warnings
   The Neuron MAX System should only be used by physicians who have received appropriate training in interventional tech-
- niques.

  Precautions

  The device is intended for single use only. Do not resterilize or reuse. Resterilization and/or reuse may result in ineffective catheter coating lubrication, which may result in high friction and the inability to access the target vasculature location; and/or compromise the structural integrity of the device.

  Do not use kinked or damaged devices. Do not use open or damaged packages. Return all defective devices and packaging
- to the manufacture/userbusin.
  Use prior to the "Use By" date.
  Use the Neuron MAX System in conjunction with fluoroscopic visualization.
  Do not advance or withdraw the Neuron MAX System against resistance without careful assessment of the cause using fluoroscopy. If the cause cannot be determined, withdraw the device. Unrestrained moving or forquing the device against

Thuoroscopy. If the cause cannot be determined, withdraw the device, unrestrained moving or torquing the device against resistance may result in damage to the vessel or device.

Maintain a constant infusion of appropriate flush solution.

If flow through the device becomes restricted, do not attempt to clear the lumen by infusion. Remove and replace the device.

Potential Adverse Events

Possible complications include, but are not limited to, the following:

- acute occlusion, air embolism, death, distal embolization, emboli, false aneurysm formation, hematoma or hemorrhage at puncture site, infection, intracranial hemorrhage, ischemia, neurological deficits including stroke, vessel spasm, thrombosis, riissection or perforation. dissection, or perforation

Product availability varies by country. Prior to use, please refer to the instructions for Use for Penumbra System with 3D Revascularization Device, Penumbra System, Penumbra Pump MAX, Neuron MAX System, Penumbra Delivery Microcatheters for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. Please contact your local Penumbra representative for more information.



Penumbra Europe GmbH

Am Borsigturm 44 13507 Berlin Germany
T +49 30 2005 676-0
T +49 30 2005 676-10
de-order@penumbrainc.de Penumbra, Inc. USA One Penumbra Place Alameda, CA 94502 888 272 4606 T 1.510.748.3200 F 1.510.748.3232 order@penumbrainc.com info@penumbrainc.com